This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: June 1, 2007
Last updated: October 27, 2010
Last verified: October 2010
CP-866,087 is a non-hormonal compound, acting on the central nervous system, which has been shown in animal models to restore sexual function.

Condition Intervention Phase
Sexual Dysfunction, Physiological Drug: CP-866,087 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2a Multi-Centre, Double Blind, Placebo Controlled Cross-Over Trial To Investigate The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women Diagnosed With Female Sexual Arousal Disorder (FSAD).

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Diary events, including Satisfactory Sexual Experiences (SSEs) over 6 weeks. [ Time Frame: 6 weeks ]
  • Score in Abbreviated Sexual Function Questionnaire after 6 weeks of treatment. [ Time Frame: 6 weeks ]

Secondary Outcome Measures:
  • Exit interview at end of study. Meaningful Benefit Question at end of study. [ Time Frame: End of study ]
  • Measure of Female Sexual Distress questionnaire after 6 weeks of treatment. [ Time Frame: 6 weeks ]

Estimated Enrollment: 84
Study Start Date: July 2007
Study Completion Date: October 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 mg Drug: CP-866,087
Tablets for oral administration
Experimental: 10 mg Drug: CP-866,087
Tablets for oral administration
Experimental: 3 mg Drug: CP-866,087
Tablets for oral administration
Placebo Comparator: Placebo Drug: Placebo
Tablets for oral administration


Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • healthy pre-menopausal women
  • primary female sexual arousal disorder causing distress
  • on stable use of oral contraceptives

Exclusion Criteria:

  • any other significant disease causing Female Sexual Dysfunction including psychiatric disease
  • subjects on drugs known to cause Female Sexual Dysfunction
  • subjects who have given birth in the last 12 months or who are planning to become pregnant during the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00482664

Australia, South Australia
Pfizer Investigational Site
Dulwich, South Australia, Australia, 5065
Australia, Western Australia
Pfizer Investigational Site
Nedlands, Western Australia, Australia, 6009
Pfizer Investigational Site
Aarhus C, Denmark, 8000
Pfizer Investigational Site
Kobenhavn OE, Denmark, 2100
Pfizer Investigational Site
Odense C, Denmark, 5000
Pfizer Investigational Site
Oslo, Norway, 0277
South Africa
Pfizer Investigational Site
Westville, Kwa-Zulu Natal, South Africa, 3629
Pfizer Investigational Site
Pretoria, South Africa, 0132
Pfizer Investigational Site
Lund, Sweden, 221 85
Pfizer Investigational Site
Skovde, Sweden, 541 30
Pfizer Investigational Site
Stockholm, Sweden, 141 86
Pfizer Investigational Site
Stockholm, Sweden, S-182 88
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer Inc Identifier: NCT00482664     History of Changes
Other Study ID Numbers: A5051017
Study First Received: June 1, 2007
Last Updated: October 27, 2010

Additional relevant MeSH terms:
Sexual Dysfunctions, Psychological
Sexual Dysfunction, Physiological
Mental Disorders
Genital Diseases, Male
Genital Diseases, Female processed this record on August 18, 2017